CSL LIMITED - Announcements

0.35%

$264.75

Market Cap $127.7B

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

CSL	CSL Half Year Results Investor Presentation	PRICE SENSITIVE	11/02/25	2.06MB	Share
CSL	CSL Half Year Results Announcement	PRICE SENSITIVE	11/02/25	358.59KB	Share
CSL	CSL Statutory Accounts for the Half Year Ended 31 Dec 2024	PRICE SENSITIVE	11/02/25	1.55MB	Share
CSL	Results Presentation	PRICE SENSITIVE	13/08/24	1.98MB	Share
CSL	Results Announcement	PRICE SENSITIVE	13/08/24	209.63KB	Share
CSL	Full Year Statutory Accounts for 30 June 2024	PRICE SENSITIVE	13/08/24	9.85MB	Share
CSL	Half Year Results Investor Presentation	PRICE SENSITIVE	13/02/24	2.29MB	Share
CSL	Half Year Results Announcement	PRICE SENSITIVE	13/02/24	270.83KB	Share
CSL	Statutory Accounts for the Half Year Ended 31 December 2023	PRICE SENSITIVE	13/02/24	1.64MB	Share
CSL	Top-line Results from the Phase 3 AEGIS-II Trial	PRICE SENSITIVE	12/02/24	143.34KB	Share
CSL	CSL Capital Markets Day	PRICE SENSITIVE	16/10/23	6.61MB	Share
CSL	CSL Results Presentation	PRICE SENSITIVE	15/08/23	2.65MB	Share
CSL	CSL Results Announcement	PRICE SENSITIVE	15/08/23	206.78KB	Share
CSL	CSL Statutory Accounts for the Full Year Ended 30 June 202	PRICE SENSITIVE	15/08/23	7.12MB	Share
CSL	Market Update	PRICE SENSITIVE	14/06/23	185.35KB	Share
CSL	CSL Half Year Results Announcement & Investor Presentation	PRICE SENSITIVE	14/02/23	2.19MB	Share
CSL	CSL Statutory Accounts for the Half Year Ended 31 Dec 2022	PRICE SENSITIVE	14/02/23	940.02KB	Share
CSL	Appointment of CSLs next CEO & Managing Director	PRICE SENSITIVE	13/12/22	167.91KB	Share
CSL	CSL Vifor Market Briefing	PRICE SENSITIVE	17/10/22	2.81MB	Share
CSL	CSL Results Presentation	PRICE SENSITIVE	17/08/22	2.06MB	Share
CSL	CSL Results Announcement	PRICE SENSITIVE	17/08/22	185.98KB	Share
CSL	CSL Statutory Accounts for the Full Year Ended 30 June 202	PRICE SENSITIVE	17/08/22	3.13MB	Share
CSL	Finalisation of Vifor Pharma Acquisition	PRICE SENSITIVE	02/08/22	111.59KB	Share
CSL	Vifor update ASX Announcement for lodgement	PRICE SENSITIVE	12/05/22	135.46KB	Share
CSL	CSL successfully issues bonds in US debt markets	PRICE SENSITIVE	21/04/22	130KB	Share
CSL	Update on Acquisition of Vifor Pharma	PRICE SENSITIVE	03/03/22	193.36KB	Share
CSL	Half Year Results Investor Presentation	PRICE SENSITIVE	16/02/22	2.52MB	Share
CSL	Half Year Results Announcement	PRICE SENSITIVE	16/02/22	466.52KB	Share
CSL	Statutory Accounts for Half Year Ended 31 December 2021	PRICE SENSITIVE	16/02/22	532.26KB	Share
CSL	CSL completes A$750 million Share Purchase Plan	PRICE SENSITIVE	14/02/22	143.3KB	Share
CSL	Successful Completion of A$6.3B Institutional Placement	PRICE SENSITIVE	16/12/21	180.03KB	Share
CSL	Investor Presentation CSL Swiss Tender Acquisition of Vifor	PRICE SENSITIVE	14/12/21	2.92MB	Share
CSL	SWISS TENDER OFFER TO ACQUIRE 100% OF VIFOR PHARMA LTD	PRICE SENSITIVE	14/12/21	595.93KB	Share
CSL	Trading Halt	PRICE SENSITIVE	14/12/21	537.08KB	Share
CSL	CSL Results Presentation	PRICE SENSITIVE	18/08/21	2.54MB	Share
CSL	CSL Results Announcement	PRICE SENSITIVE	18/08/21	426.28KB	Share
CSL	CSL Statutory Accounts for the Full Year Ended 30 June 2021	PRICE SENSITIVE	18/08/21	2.79MB	Share
CSL	Update on CSL Agreement with uniQure	PRICE SENSITIVE	06/05/21	117.89KB	Share
CSL	Half Year Results Investor Presentation	PRICE SENSITIVE	18/02/21	2.64MB	Share
CSL	Half Year Results Announcement	PRICE SENSITIVE	18/02/21	257.68KB	Share
CSL	Dividend/Distribution - CSL	PRICE SENSITIVE	18/02/21	24.76KB	Share
CSL	Statutory Accounts for the Half Year Ended 31 Dec 2020	PRICE SENSITIVE	18/02/21	827.94KB	Share
CSL	Update on UQ-CSL v451 COVID-19 Vaccine	PRICE SENSITIVE	11/12/20	121.88KB	Share
CSL	Chairman's Address to Shareholders	PRICE SENSITIVE	14/10/20	3.63MB	Share
CSL	CSL Supply Agreement for UQ Vaccine with Commonwealth	PRICE SENSITIVE	08/10/20	148.37KB	Share
CSL	CSL Results Presentation	PRICE SENSITIVE	19/08/20	3.07MB	Share
CSL	CSL Results Announcement	PRICE SENSITIVE	19/08/20	406.12KB	Share
CSL	Statutory Accounts for the Full Year Ended 30 June 2020	PRICE SENSITIVE	19/08/20	7.14MB	Share
CSL	CSL to acquire LateStage Gene Therapy Candidate from uniQure	PRICE SENSITIVE	25/06/20	154.71KB	Share
CSL	Change in Leadership of CSL's Finance Function	PRICE SENSITIVE	17/06/20	115.6KB	Share
CSL	New Debt Facilities to Strengthen Maturity Profile	PRICE SENSITIVE	07/05/20	181.86KB	Share
CSL	CSL Half Year Results Investor Presentation	PRICE SENSITIVE	12/02/20	2.59MB	Share
CSL	CSL Half Year Results Announcement	PRICE SENSITIVE	12/02/20	259.09KB	Share
CSL	CSL Statutory Accounts for the Half Year Ended 31/12/2019	PRICE SENSITIVE	12/02/20	487.02KB	Share
CSL	Research and Development Investor Briefing 2019	PRICE SENSITIVE	04/12/19	12.36MB	Share
CSL	CSL Results Presentation	PRICE SENSITIVE	14/08/19	2.96MB	Share
CSL	CSL Results Announcement	PRICE SENSITIVE	14/08/19	250.15KB	Share
CSL	CSL Full Year Statutory Accounts for the Year Ended 30/06/19	PRICE SENSITIVE	14/08/19	2.88MB	Share
CSL	UPDATE ON CSL TRANSITION TO OWN DISTRIBUTOR MODEL IN CHINA	PRICE SENSITIVE	21/06/19	177.08KB	Share
CSL	Half Year Results Analyst Presentation	PRICE SENSITIVE	13/02/19	2.6MB	Share
CSL	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	13/02/19	889.89KB	Share
CSL	CSL R&D Investor Briefing	PRICE SENSITIVE	05/12/18	4.19MB	Share
CSL	Full Year Results Announcement	PRICE SENSITIVE	15/08/18	183.69KB	Share
CSL	Full Year Statutory Accounts	PRICE SENSITIVE	15/08/18	1.12MB	Share
CSL	CSL Lifts Profit Guidance	PRICE SENSITIVE	18/05/18	400.28KB	Share
CSL	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	14/02/18	289.9KB	Share
CSL	PGC: Acquisition of Immunohaematology Business	PRICE SENSITIVE	01/12/17	609.86KB	Share
CSL	CEO's AGM Presentation	PRICE SENSITIVE	18/10/17	1.04MB	Share
CSL	New Debt Facilities	PRICE SENSITIVE	05/10/17	103.3KB	Share
CSL	FDA Approves Privigen for CIDP Indication	PRICE SENSITIVE	15/09/17	54.68KB	Share
CSL	CSL Behring Acquires US Biotech Company Calimmune	PRICE SENSITIVE	28/08/17	102.05KB	Share
CSL	2017 FY Results Announcement and Analysts Presentation	PRICE SENSITIVE	16/08/17	2.46MB	Share
CSL	Appendix 4E, Directors Report and Financial Statements	PRICE SENSITIVE	16/08/17	1.18MB	Share
CSL	CSL Completes Acquisition of Majority Stake in Ruide	PRICE SENSITIVE	03/08/17	52.67KB	Share
CSL	CSL Response to Patent Infringement Complaint	PRICE SENSITIVE	10/07/17	48.72KB	Share
CSL	FDA approves CSL Berhing's HAEGARDA	PRICE SENSITIVE	23/06/17	72.12KB	Share
CSL	CSL to Acquire Majority Stake in Chinese Plasma Fractionator	PRICE SENSITIVE	13/06/17	1.47MB	Share
CSL	Half Year Results Release	PRICE SENSITIVE	15/02/17	101.27KB	Share
CSL	Half Year Results Analysts Presentation	PRICE SENSITIVE	15/02/17	910.84KB	Share
CSL	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	15/02/17	253KB	Share
CSL	FY2017 Profit Upgrade	PRICE SENSITIVE	19/01/17	67.06KB	Share
CSL	AFSTYLA (rFVIII-Single Chain) European Commission Approval	PRICE SENSITIVE	09/01/17	52.84KB	Share
CSL	Positive Results from CSL112 Phase 2b Trial	PRICE SENSITIVE	16/11/16	75.86KB	Share
CSL	Afstyla CHMP Recommendation	PRICE SENSITIVE	14/11/16	51.72KB	Share
CSL	New Debt Facilities-CSL.AX	PRICE SENSITIVE	14/10/16	57.32KB	Share
CSL	Chairman's Address to Shareholders-CSL.AX	PRICE SENSITIVE	12/10/16	79.67KB	Share
CSL	FDA Accepts BLA for Hereditary Angioedema Therapy-CSL.AX	PRICE SENSITIVE	30/08/16	52.82KB	Share
CSL	2016 FY Results Announcements and Analysts Briefing-CSL.AX	PRICE SENSITIVE	17/08/16	1.77MB	Share
CSL	Appendix 4E, Directors Report and Financial Statements-CSL.AX	PRICE SENSITIVE	17/08/16	1.22MB	Share
CSL	AFSTYLA (rFVIII-Single Chain) FDA approval-CSL.AX	PRICE SENSITIVE	26/05/16	52.73KB	Share
CSL	AFSTYLA (rFVIII-Single Chain) FDA approval-CSL.AX	PRICE SENSITIVE	26/05/16		Share
CSL	Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval-CSL.AX	PRICE SENSITIVE	24/05/16	52.43KB	Share
CSL	IDELVION(R) (rFIX-FP) - European Commission Approval-CSL.AX	PRICE SENSITIVE	12/05/16	53.17KB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	23/03/16	76.83KB	Share
CSL	IDELVION(R) (rFIX-FP) - FDA approval	PRICE SENSITIVE	07/03/16	52.73KB	Share
CSL	IDELVION(R) (rFIX-FP) - CHMP recommendation	PRICE SENSITIVE	29/02/16	51.87KB	Share
CSL	Half Year Accounts	PRICE SENSITIVE	16/02/16	556.03KB	Share
CSL	New Debt Facilities	PRICE SENSITIVE	21/12/15	46.03KB	Share
CSL	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	15/10/15	82.77KB	Share
CSL	New US Private Placement	PRICE SENSITIVE	09/10/15	59.1KB	Share

CSL CSL Half Year Results Investor Presentation
11/02/25	PRICE SENSITIVE	2.06MB	Share
CSL CSL Half Year Results Announcement
11/02/25	PRICE SENSITIVE	358.59KB	Share
CSL CSL Statutory Accounts for the Half Year Ended 31 Dec 2024
11/02/25	PRICE SENSITIVE	1.55MB	Share
CSL Results Presentation
13/08/24	PRICE SENSITIVE	1.98MB	Share
CSL Results Announcement
13/08/24	PRICE SENSITIVE	209.63KB	Share
CSL Full Year Statutory Accounts for 30 June 2024
13/08/24	PRICE SENSITIVE	9.85MB	Share
CSL Half Year Results Investor Presentation
13/02/24	PRICE SENSITIVE	2.29MB	Share
CSL Half Year Results Announcement
13/02/24	PRICE SENSITIVE	270.83KB	Share
CSL Statutory Accounts for the Half Year Ended 31 December 2023
13/02/24	PRICE SENSITIVE	1.64MB	Share
CSL Top-line Results from the Phase 3 AEGIS-II Trial
12/02/24	PRICE SENSITIVE	143.34KB	Share
CSL CSL Capital Markets Day
16/10/23	PRICE SENSITIVE	6.61MB	Share
CSL CSL Results Presentation
15/08/23	PRICE SENSITIVE	2.65MB	Share
CSL CSL Results Announcement
15/08/23	PRICE SENSITIVE	206.78KB	Share
CSL CSL Statutory Accounts for the Full Year Ended 30 June 202
15/08/23	PRICE SENSITIVE	7.12MB	Share
CSL Market Update
14/06/23	PRICE SENSITIVE	185.35KB	Share
CSL CSL Half Year Results Announcement & Investor Presentation
14/02/23	PRICE SENSITIVE	2.19MB	Share
CSL CSL Statutory Accounts for the Half Year Ended 31 Dec 2022
14/02/23	PRICE SENSITIVE	940.02KB	Share
CSL Appointment of CSLs next CEO & Managing Director
13/12/22	PRICE SENSITIVE	167.91KB	Share
CSL CSL Vifor Market Briefing
17/10/22	PRICE SENSITIVE	2.81MB	Share
CSL CSL Results Presentation
17/08/22	PRICE SENSITIVE	2.06MB	Share
CSL CSL Results Announcement
17/08/22	PRICE SENSITIVE	185.98KB	Share
CSL CSL Statutory Accounts for the Full Year Ended 30 June 202
17/08/22	PRICE SENSITIVE	3.13MB	Share
CSL Finalisation of Vifor Pharma Acquisition
02/08/22	PRICE SENSITIVE	111.59KB	Share
CSL Vifor update ASX Announcement for lodgement
12/05/22	PRICE SENSITIVE	135.46KB	Share
CSL CSL successfully issues bonds in US debt markets
21/04/22	PRICE SENSITIVE	130KB	Share
CSL Update on Acquisition of Vifor Pharma
03/03/22	PRICE SENSITIVE	193.36KB	Share
CSL Half Year Results Investor Presentation
16/02/22	PRICE SENSITIVE	2.52MB	Share
CSL Half Year Results Announcement
16/02/22	PRICE SENSITIVE	466.52KB	Share
CSL Statutory Accounts for Half Year Ended 31 December 2021
16/02/22	PRICE SENSITIVE	532.26KB	Share
CSL CSL completes A$750 million Share Purchase Plan
14/02/22	PRICE SENSITIVE	143.3KB	Share
CSL Successful Completion of A$6.3B Institutional Placement
16/12/21	PRICE SENSITIVE	180.03KB	Share
CSL Investor Presentation CSL Swiss Tender Acquisition of Vifor
14/12/21	PRICE SENSITIVE	2.92MB	Share
CSL SWISS TENDER OFFER TO ACQUIRE 100% OF VIFOR PHARMA LTD
14/12/21	PRICE SENSITIVE	595.93KB	Share
CSL Trading Halt
14/12/21	PRICE SENSITIVE	537.08KB	Share
CSL CSL Results Presentation
18/08/21	PRICE SENSITIVE	2.54MB	Share
CSL CSL Results Announcement
18/08/21	PRICE SENSITIVE	426.28KB	Share
CSL CSL Statutory Accounts for the Full Year Ended 30 June 2021
18/08/21	PRICE SENSITIVE	2.79MB	Share
CSL Update on CSL Agreement with uniQure
06/05/21	PRICE SENSITIVE	117.89KB	Share
CSL Half Year Results Investor Presentation
18/02/21	PRICE SENSITIVE	2.64MB	Share
CSL Half Year Results Announcement
18/02/21	PRICE SENSITIVE	257.68KB	Share
CSL Dividend/Distribution - CSL
18/02/21	PRICE SENSITIVE	24.76KB	Share
CSL Statutory Accounts for the Half Year Ended 31 Dec 2020
18/02/21	PRICE SENSITIVE	827.94KB	Share
CSL Update on UQ-CSL v451 COVID-19 Vaccine
11/12/20	PRICE SENSITIVE	121.88KB	Share
CSL Chairman's Address to Shareholders
14/10/20	PRICE SENSITIVE	3.63MB	Share
CSL CSL Supply Agreement for UQ Vaccine with Commonwealth
08/10/20	PRICE SENSITIVE	148.37KB	Share
CSL CSL Results Presentation
19/08/20	PRICE SENSITIVE	3.07MB	Share
CSL CSL Results Announcement
19/08/20	PRICE SENSITIVE	406.12KB	Share
CSL Statutory Accounts for the Full Year Ended 30 June 2020
19/08/20	PRICE SENSITIVE	7.14MB	Share
CSL CSL to acquire LateStage Gene Therapy Candidate from uniQure
25/06/20	PRICE SENSITIVE	154.71KB	Share
CSL Change in Leadership of CSL's Finance Function
17/06/20	PRICE SENSITIVE	115.6KB	Share
CSL New Debt Facilities to Strengthen Maturity Profile
07/05/20	PRICE SENSITIVE	181.86KB	Share
CSL CSL Half Year Results Investor Presentation
12/02/20	PRICE SENSITIVE	2.59MB	Share
CSL CSL Half Year Results Announcement
12/02/20	PRICE SENSITIVE	259.09KB	Share
CSL CSL Statutory Accounts for the Half Year Ended 31/12/2019
12/02/20	PRICE SENSITIVE	487.02KB	Share
CSL Research and Development Investor Briefing 2019
04/12/19	PRICE SENSITIVE	12.36MB	Share
CSL CSL Results Presentation
14/08/19	PRICE SENSITIVE	2.96MB	Share
CSL CSL Results Announcement
14/08/19	PRICE SENSITIVE	250.15KB	Share
CSL CSL Full Year Statutory Accounts for the Year Ended 30/06/19
14/08/19	PRICE SENSITIVE	2.88MB	Share
CSL UPDATE ON CSL TRANSITION TO OWN DISTRIBUTOR MODEL IN CHINA
21/06/19	PRICE SENSITIVE	177.08KB	Share
CSL Half Year Results Analyst Presentation
13/02/19	PRICE SENSITIVE	2.6MB	Share
CSL Appendix 4D and Half Year Accounts
13/02/19	PRICE SENSITIVE	889.89KB	Share
CSL CSL R&D Investor Briefing
05/12/18	PRICE SENSITIVE	4.19MB	Share
CSL Full Year Results Announcement
15/08/18	PRICE SENSITIVE	183.69KB	Share
CSL Full Year Statutory Accounts
15/08/18	PRICE SENSITIVE	1.12MB	Share
CSL CSL Lifts Profit Guidance
18/05/18	PRICE SENSITIVE	400.28KB	Share
CSL Appendix 4D and Half Year Accounts
14/02/18	PRICE SENSITIVE	289.9KB	Share
CSL PGC: Acquisition of Immunohaematology Business
01/12/17	PRICE SENSITIVE	609.86KB	Share
CSL CEO's AGM Presentation
18/10/17	PRICE SENSITIVE	1.04MB	Share
CSL New Debt Facilities
05/10/17	PRICE SENSITIVE	103.3KB	Share
CSL FDA Approves Privigen for CIDP Indication
15/09/17	PRICE SENSITIVE	54.68KB	Share
CSL CSL Behring Acquires US Biotech Company Calimmune
28/08/17	PRICE SENSITIVE	102.05KB	Share
CSL 2017 FY Results Announcement and Analysts Presentation
16/08/17	PRICE SENSITIVE	2.46MB	Share
CSL Appendix 4E, Directors Report and Financial Statements
16/08/17	PRICE SENSITIVE	1.18MB	Share
CSL CSL Completes Acquisition of Majority Stake in Ruide
03/08/17	PRICE SENSITIVE	52.67KB	Share
CSL CSL Response to Patent Infringement Complaint
10/07/17	PRICE SENSITIVE	48.72KB	Share
CSL FDA approves CSL Berhing's HAEGARDA
23/06/17	PRICE SENSITIVE	72.12KB	Share
CSL CSL to Acquire Majority Stake in Chinese Plasma Fractionator
13/06/17	PRICE SENSITIVE	1.47MB	Share
CSL Half Year Results Release
15/02/17	PRICE SENSITIVE	101.27KB	Share
CSL Half Year Results Analysts Presentation
15/02/17	PRICE SENSITIVE	910.84KB	Share
CSL Appendix 4D and Half Year Accounts
15/02/17	PRICE SENSITIVE	253KB	Share
CSL FY2017 Profit Upgrade
19/01/17	PRICE SENSITIVE	67.06KB	Share
CSL AFSTYLA (rFVIII-Single Chain) European Commission Approval
09/01/17	PRICE SENSITIVE	52.84KB	Share
CSL Positive Results from CSL112 Phase 2b Trial
16/11/16	PRICE SENSITIVE	75.86KB	Share
CSL Afstyla CHMP Recommendation
14/11/16	PRICE SENSITIVE	51.72KB	Share
CSL New Debt Facilities-CSL.AX
14/10/16	PRICE SENSITIVE	57.32KB	Share
CSL Chairman's Address to Shareholders-CSL.AX
12/10/16	PRICE SENSITIVE	79.67KB	Share
CSL FDA Accepts BLA for Hereditary Angioedema Therapy-CSL.AX
30/08/16	PRICE SENSITIVE	52.82KB	Share
CSL 2016 FY Results Announcements and Analysts Briefing-CSL.AX
17/08/16	PRICE SENSITIVE	1.77MB	Share
CSL Appendix 4E, Directors Report and Financial Statements-CSL.AX
17/08/16	PRICE SENSITIVE	1.22MB	Share
CSL AFSTYLA (rFVIII-Single Chain) FDA approval-CSL.AX
26/05/16	PRICE SENSITIVE	52.73KB	Share
CSL AFSTYLA (rFVIII-Single Chain) FDA approval-CSL.AX
26/05/16	PRICE SENSITIVE		Share
CSL Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval-CSL.AX
24/05/16	PRICE SENSITIVE	52.43KB	Share
CSL IDELVION(R) (rFIX-FP) - European Commission Approval-CSL.AX
12/05/16	PRICE SENSITIVE	53.17KB	Share
CSL Changes relating to buy-back - Appendix 3D
23/03/16	PRICE SENSITIVE	76.83KB	Share
CSL IDELVION(R) (rFIX-FP) - FDA approval
07/03/16	PRICE SENSITIVE	52.73KB	Share
CSL IDELVION(R) (rFIX-FP) - CHMP recommendation
29/02/16	PRICE SENSITIVE	51.87KB	Share
CSL Half Year Accounts
16/02/16	PRICE SENSITIVE	556.03KB	Share
CSL New Debt Facilities
21/12/15	PRICE SENSITIVE	46.03KB	Share
CSL Announcement of buy-back - Appendix 3C
15/10/15	PRICE SENSITIVE	82.77KB	Share
CSL New US Private Placement
09/10/15	PRICE SENSITIVE	59.1KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $264.75		Change 0.930(0.35%)		Mkt cap ! $127.7B

Open	High	Low	Value	Volume
$263.30	$264.79	$263.02	$19.30M	73.16K

Buyers (Bids)

No.	Vol.	Price($)
2	8	$264.75

Sellers (Offers)

Price($)	Vol.	No.
$264.79	57	3

View Market Depth

No.	Vol.	Price($)
1	15	264.150
3	14	264.140
1	25	264.130
3	33	264.090
4	30	264.080

Price($)	Vol.	No.
264.180	82	4
264.190	1	1
264.200	141	4
264.210	15	2
264.220	117	2

Last trade - 11.26am 12/08/2025 (20 minute delay)


Last $264.88		Change 0.930 ( 0.55 %)
Open	High	Low	Volume
$263.85	$265.28	$263.02	19117
Last updated 11.45am 12/08/2025 ?

CSL (ASX) Chart

CSL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories